Integrated molecular drivers coordinate biological and clinical states in melanoma

We performed harmonized molecular and clinical analysis on 1,048 melanomas and discovered markedly different global genomic properties among subtypes (BRAF, (N)RAS, NF1, triple wild-type (TWT)), subtype-specific preferences for secondary driver genes and active mutational processes previously unrepo...

Full description

Saved in:
Bibliographic Details
Published inNature genetics Vol. 52; no. 12; pp. 1373 - 1383
Main Authors Conway, Jake R, Dietlein, Felix, Taylor-Weiner, Amaro, AlDubayan, Saud, Vokes, Natalie, Keenan, Tanya, Reardon, Brendan, He, Meng Xiao, Margolis, Claire A, Weirather, Jason L, Haq, Rizwan, Schilling, Bastian, Stephen Hodi, F, Schadendorf, Dirk, Liu, David, Van Allen, Eliezer M
Format Journal Article
LanguageEnglish
Published United States Nature Publishing Group 01.12.2020
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We performed harmonized molecular and clinical analysis on 1,048 melanomas and discovered markedly different global genomic properties among subtypes (BRAF, (N)RAS, NF1, triple wild-type (TWT)), subtype-specific preferences for secondary driver genes and active mutational processes previously unreported in melanoma. Secondary driver genes significantly enriched in specific subtypes reflected preferential dysregulation of additional pathways, such as induction of transforming growth factor-β signaling in BRAF melanomas and inactivation of the SWI/SNF complex in (N)RAS melanomas, and select co-mutation patterns coordinated selective response to immune checkpoint blockade. We also defined the mutational landscape of TWT melanomas and revealed enrichment of DNA-repair-defect signatures in this subtype, which were associated with transcriptional downregulation of key DNA-repair genes, and may revive previously discarded or currently unconsidered therapeutic modalities for genomically stratified melanoma patient subsets. Broadly, harmonized meta-analysis of melanoma whole exomes revealed distinct molecular drivers that may point to multiple opportunities for biological and therapeutic investigation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
AUTHOR CONTRIBUTIONS
J.R.C., A.T.W., S.A., F.D., B.R. and M.X.H. contributed to the analysis of genomic data. J.R.C., C.A.M., B.S., D.S., D.L., E.M.V.A. contributed to aggregation of raw sequence data. N.V., T.K., D.L. and E.M.V.A. contributed to analysis and data interpretation of immunotherapy response. J.R.C., A.T.W., S.A., N.V., F.D., B.R., J.W., R.H., F.S.H., B.S., D.S., D.L., and E.M.V.A. contributed to interpretation of results, and manuscript preparation.
ISSN:1061-4036
1546-1718
DOI:10.1038/s41588-020-00739-1